AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu
AstraZeneca and Daiichi Sankyo have formed a global partnership to jointly develop and commercialize Enhertu, an antibody drug conjugate.
Daiichi Sankyo and GAIA join forces to commercialise digital therapeutic for high cholesterol
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
Daiichi Sankyo to Merge with Wholly Owned Subsidiary Daiichi Sankyo Propharma
AstraZeneca and Daiichi Sankyo have entered into a new global development and commercialization agreement for a jointly developed antibody drug conjugate.
Where this signal fits in the broader landscape.
https://www.marketscreener.com/news/astrazeneca-and-daiichi-sankyo-enter-global-collaboration-to-jointly-develop-and-commercialize-enher-ce7e5fdeda8cf522
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
Sign In